AUTHOR=Wang Luo , Mou Haibo , Hou Xuehua , Liao Qin 

TITLE=Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1126769

DOI=10.3389/fonc.2023.1126769

ISSN=2234-943X

ABSTRACT=Immune checkpoint inhibitor (ICI)s have dramatically transformed the treatment landscape for metastatic colorectal cancer(mCRC) with deficient DNA mismatch repair(dMMR) or microsatellite instability-high(MSI-H). Envafolimab, a novel programmed death-1 ligand 1(PD-L1) inhibitor, was reported to be efficient and manageable of safety in MSI-H/dMMR advanced solid tumors. Here, we report a case of a   35-year-old female with MSI-H/dMMR mCRC who adapted envafolimab after the use of mFOLFOX6(oxaliplatin, leucovorin, and fluorouracil) plus bevacizumab. While suffered interstitial pneumonia after chemotherapy,
she ultimately achieved clinical complete response with the use of envafolimab without additional adverse events. For patients with MSI-H/dMMR mCRC, PD-L1 inhibitor may be a potential candidate.